Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
22. Essig M, Nguyen O, Prie D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reduc-tase inhibitors increase fibrinolytik activity in rat aortic endothelial cells: role of genylgera-nyla-tion and Rho proteins. Circ Res. 1998; 83: 683— 690.
23. Hernandez-Perera O, Perez-Sala D, Na-varro-Anlolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, ator-vastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide syn-
thase in vascular endothelial cells. J Clin Invest 1998; 101: 2711—2719.
24. Rikitake Y, Kawashima S, Takeshita S, et al. Anli-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87—96.
25. Wassman S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angio-gensin II-mediated free radical production in vascular smoth muscle cells: involvment of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646—654.
26. Inoue I, Goto S, Mootani K, et al. Lipo-philic HMG-CoA reductase inhibitor has an antiinflammatory effect: reduction of MRNA levels for interleukin-1 beta, interleukin-6. cyclooxygenase-2, andp22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARal-pha) in primary endothelial cells. Life Sci 2000; 67: 863—876.
27. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokin in rat primary astrocyles. microglia, and macro-phages. J Clin Invest. 1997; 100: 2671—2679.
28. Kothe H, DalhoffK, Rupp J, et al. Hydro-xymelhylglutaryl coenzyme: a reductase inhibitors modify the inflammalory response of human macrophages and endothelial cells infected with Chlamydia pneumonia. Circulation 2000; 101: 4760—1763.
29. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Isioivastatin preserves the ischemk-reperfused myocardium in nonno-/cho-lesterolemk rat hearts. Circulation. 1999; 100: 178—184.
30. Scalia R, Gooszen ME, Jones SP, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein e-defici-cnt mice. Circulation. 2001; 103: 2598—2603.
31. Gaunhier TW, Scalia R, Murohan T, et al. Nitric oxide protects against leukocyte-endotheli-um interactions in the early stages of hypercholes-terolemia. Atherioscler Tnromh Vo Blol 1995; 15: 1652 1659.
32. Giuiarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce
SHS-OOO4.qxd 21.11.2006 16:56 Page 430
Насонов Е.Л. Антифосфолипидный синдром.
apoptosts of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490 —500.
33. Bustos CC, Hemandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cordial. 1998; 2: 2057—2064.
34. Huhk G, Abklshauser C, Mayer N, et al. Reduction of platelet activity marker in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromh Res. 1999; 95: 229 —234.
35. Hale LP, Craver KT, Berrier AM, et al. Owen Combination of fosinopril and pravastatin decreases platelet response thrombin receptor agonist in monkeys. Arteroscler Thromh Vasc Biol 1998; 18:1643—1646.
36. Schror K. Platelet reactivity and arachidon-ic acid metabolism in type II hyperlipopro-teinaemia and its modification by cholesterol-lowering agents. Eicosanoids. 1990; 3: 67—73.
37. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor. cenvastatin. suppresses growth of macrophages expressing matrix metalloproteinases. and tissue factor in vivo, and in vitro. Circulation 2001; 103: 276—283.
38. Fukumoto Y, Libby P, Rahkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993—999.
39. Lijnen P, Kchevaria-Vazquez D, Petrov V. Influence of cholesterol-lowering on plasma membrane lipids and function. Methods find Exp Clin Pharmacol. I996; I8: 123—136.
40. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhevsiveness of monocytes isolated from patients with hypercholesterine-mia. J Am Col Cardiol 1997; 30: 1212—1227.
41. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7: 687—692.
42. Frenette PS. Lockin a leukocyte integrin with stastin. New Engl J Med 2001; 345:1419—1421.
43. Avimar M, Dankner G, Cogan Um, et al. Lovastatin inhibits low-densitry lipoprotein oxidation and alters its binding and uptake by macrophages in vitro and in vivo studies. Metabolism 1992; 41: 229—235.
44. Hoffman R, Brook GJ, Aviram M. Hypoli-pidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and in vivo studies. Atherosclerosis 1992; 93: 105—113.
